SCHEDULE: Ayrton Capital, Alto Fund Reduce 60 Degrees Pharma Stake to 4.14%

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have filed an amended Schedule 13G, reporting a combined beneficial ownership of 4.14% in 60 DEGREES PHARMACEUTICALS, INC.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
• As of September 30, 2025, the Reporting Persons beneficially own 177,427 shares of Common Stock in 60 DEGREES PHARMACEUTICALS, INC.
• This ownership represents 4.14% of the Issuer's outstanding Common Stock.
• The reported shares are issuable upon the exercise of certain warrants held by the Reporting Persons.
• The issuable shares from these warrants are subject to a 9.99% beneficial ownership blocker.
• The percentage of class is calculated based on 4,104,469 shares of Common Stock outstanding as of September 3, 2025, plus the 177,427 shares issuable from the warrants.
• The Reporting Persons hold sole voting and dispositive power over these 177,427 shares.
• Ayrton Capital LLC serves as the investment manager for Alto Opportunity Master Fund, and Waqas Khatri is the managing member of Ayrton Capital LLC and a director of Alto Opportunity Master Fund.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the Issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative as the filing indicates a reduction in a significant investor's stake below the 5% reporting threshold, which can be perceived as a loss of conviction or a strategic divestment.

Positives

• The filing demonstrates compliance with SEC disclosure requirements regarding beneficial ownership changes.
• The ownership is held in the ordinary course of business, indicating a passive investment intent rather than an activist one.

Negatives

• The filing indicates a reduction in beneficial ownership to below the 5% threshold, suggesting a decrease in the Reporting Persons' stake in the company from a previous reportable level.

Risks

• The warrants held by the Reporting Persons are subject to a 9.99% beneficial ownership blocker, which limits the maximum percentage of shares they can beneficially own upon exercise, potentially restricting their influence or ability to increase their stake significantly.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the Issuer's future performance or the Reporting Persons' future investment intentions beyond the current ownership disclosure.

Industry Context

This filing is a routine disclosure of a change in beneficial ownership by institutional investors in a publicly traded pharmaceutical company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The reduction in a significant investor's stake may influence market perception and potentially the share price, as it could signal a change in investor confidence or strategy.

Key Dates

Recommendation

This Schedule 13G amendment primarily discloses a reduction in beneficial ownership by a group of investors to below the 5% threshold. While this is a factual disclosure, a reduction in a significant stake can be viewed negatively by the market. However, without additional information on the company's fundamentals, operational performance, or the investors' specific reasons for reducing their stake, a definitive 'buy' or 'sell' recommendation is premature. Investors should 'hold' and monitor future company performance and further disclosures to assess the long-term implications of this change in ownership structure.

Keywords

60 DEGREES PHARMACEUTICALS, Ayrton Capital, Alto Opportunity Master Fund, Waqas Khatri, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment Management, SEC Filing